EMEA-001442-PIP01-13
Key facts
| Active substance |
|
| Therapeutic area |
Infectious diseases
|
| Decision number |
P/0001/2014
|
| PIP number |
EMEA-001442-PIP01-13
|
| Pharmaceutical form(s) |
Film-coated tablet
|
| Condition(s) / indication(s) |
Treatment of human immunodeficiency virus (HIV-1) infection
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Merck Sharp & Dohme (Europe), Inc.
|
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|
| Compliance procedure number |
EMEA-C-001442-PIP01-13
|
| Compliance opinion date |
21/03/2014
|
| Compliance outcome |
positive
|